These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 33065064)

  • 41. Combined COVID-19, Flu Vaccine Candidate Headed to Phase 3 Trials.
    Harris E
    JAMA; 2023 Dec; 330(21):2044. PubMed ID: 37966868
    [No Abstract]   [Full Text] [Related]  

  • 42. Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease.
    Cullen G; Bader C; Korzenik JR; Sands BE
    Gut; 2012 Mar; 61(3):385-91. PubMed ID: 21757451
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and immunogenicity of COVID-19 vaccination in immunocompromised patients.
    Song JW; Hu W; Shen L; Wang FS
    Chin Med J (Engl); 2022 Nov; 135(22):2656-2666. PubMed ID: 36719354
    [TBL] [Abstract][Full Text] [Related]  

  • 44. COVID-19 and rheumatology: Reflecting on the first wave and preparing for the second wave.
    Fardanesh A; Byravan S; Moorthy A; Tahir H
    Int J Rheum Dis; 2021 Jan; 24(1):7-9. PubMed ID: 33459529
    [No Abstract]   [Full Text] [Related]  

  • 45. [Vaccination against SARS-CoV-2 in patients with multiple sclerosis].
    Costa Frossard-França L; García-Domínguez JM; Moreno-Torres I; Fortún J; Villar LM; Meca-Lallana V
    Rev Neurol; 2021 Apr; 72(7):250-260. PubMed ID: 33764494
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunogenicity and Safety of Influenza Vaccine in Inflammatory Bowel Disease Patients Treated or not with Immunomodulators and/or Biologics: A Two-year Prospective Study.
    Launay O; Abitbol V; Krivine A; Slama LB; Bourreille A; Dupas JL; Hébuterne X; Savoye G; Deplanque D; Bouhnik Y; Pelletier AL; Galtier F; Laharie D; Nachury M; Zerbib F; Allez M; Bommelaer G; Duclos B; Lucht F; Gougeon ML; Tartour E; Rozenberg F; Hanslik T; Beaugerie L; Carrat F;
    J Crohns Colitis; 2015 Dec; 9(12):1096-107. PubMed ID: 26351392
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Variability in the reporting of adverse reactions to the pandemic and seasonal influenza vaccine: seasons 2009-2010 and 2010-2011. Valencian community, Spain].
    Alguacil Ramos AM; Lluch Rodrigo JA; Portero Alonso A; Martín Ivorra R; Pastor Villalba E
    Rev Esp Salud Publica; 2012; 86(3):241-51. PubMed ID: 22991081
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Flu fallout: what went wrong in 2010, and should we have seen it coming?
    McNamara S
    Med J Aust; 2011 Nov; 195(9):542-5. PubMed ID: 22060091
    [No Abstract]   [Full Text] [Related]  

  • 49. Antibody and cell-mediated immune response to whole virion and split virion influenza vaccine in patients with inflammatory bowel disease on maintenance immunosuppressive and biological therapy.
    Bálint A; Farkas K; Éva PK; Terhes G; Urbán E; Szucs M; Nyári T; Bata Z; Nagy F; Szepes Z; Miheller P; Lorinczy K; Lakatos PL; Lovász B; Tamás S; Kulcsár A; Berényi A; Törocsik D; Daróczi T; Saródi Z; Wittmann T; Molnár T
    Scand J Gastroenterol; 2015 Feb; 50(2):174-81. PubMed ID: 25384624
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influenza immunization and COVID-19.
    Maltezou HC; Theodoridou K; Poland G
    Vaccine; 2020 Sep; 38(39):6078-6079. PubMed ID: 32773245
    [No Abstract]   [Full Text] [Related]  

  • 51. COVID-19 mRNA Vaccine Short-Term Safety in Patients With Inflammatory Bowel Disease.
    Spiera E; Agrawal M; Ungaro RC
    Gastroenterology; 2022 Mar; 162(3):987-988. PubMed ID: 34626602
    [No Abstract]   [Full Text] [Related]  

  • 52. Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines.
    Schulze-Koops H; Specker C; Skapenko A
    RMD Open; 2021 Feb; 7(1):. PubMed ID: 33627439
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease.
    deBruyn JC; Hilsden R; Fonseca K; Russell ML; Kaplan GG; Vanderkooi O; Wrobel I
    Inflamm Bowel Dis; 2012 Jan; 18(1):25-33. PubMed ID: 21472826
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relief and worry for immune-suppressed people.
    Couzin-Frankel J
    Science; 2021 Apr; 372(6541):443-444. PubMed ID: 33926929
    [No Abstract]   [Full Text] [Related]  

  • 55. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease.
    Kucharzik T; Ellul P; Greuter T; Rahier JF; Verstockt B; Abreu C; Albuquerque A; Allocca M; Esteve M; Farraye FA; Gordon H; Karmiris K; Kopylov U; Kirchgesner J; MacMahon E; Magro F; Maaser C; de Ridder L; Taxonera C; Toruner M; Tremblay L; Scharl M; Viget N; Zabana Y; Vavricka S
    J Crohns Colitis; 2021 Jun; 15(6):879-913. PubMed ID: 33730753
    [No Abstract]   [Full Text] [Related]  

  • 56. Pneumococcal and influenza vaccine uptake in adults with inflammatory bowel disease in France: Results from a web-based study.
    Loubet P; Verger P; Abitbol V; Peyrin-Biroulet L; Launay O
    Dig Liver Dis; 2018 Jun; 50(6):563-567. PubMed ID: 29371056
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunization against influenza during the 2005/2006 epidemic season and the humoral response in children with diagnosed inflammatory bowel disease (IBD).
    Romanowska M; Banaszkiewicz A; Nowak I; Radzikowski A; Brydak LB
    Med Sci Monit; 2010 Sep; 16(9):CR433-9. PubMed ID: 20802416
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vaccinating children against influenza increases variability in epidemic size.
    Backer JA; van Boven M; van der Hoek W; Wallinga J
    Epidemics; 2019 Mar; 26():95-103. PubMed ID: 30529023
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vaccines against influenza WHO position paper – November 2012.
    Wkly Epidemiol Rec; 2012 Nov; 87(47):461-76. PubMed ID: 23210147
    [No Abstract]   [Full Text] [Related]  

  • 60. Evaluation of pandemic H1N1 (2009) influenza vaccine in adults with solid tumor and hematological malignancies on active systemic treatment.
    Mackay HJ; McGee J; Villa D; Gubbay JB; Tinker LM; Shi L; Kuruvilla J; Wang L; MacAlpine K; Oza AM
    J Clin Virol; 2011 Mar; 50(3):212-6. PubMed ID: 21168361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.